Valerio Therapeutics S.A.
ALVIO.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €1,793 | €1,800 | €1,443 | €4,062 |
| % Growth | -0.4% | 24.7% | -64.5% | – |
| Cost of Goods Sold | €513 | €533 | €514 | €368 |
| Gross Profit | €1,280 | €1,267 | €929 | €3,694 |
| % Margin | 71.4% | 70.4% | 64.4% | 90.9% |
| R&D Expenses | €5,144 | €9,679 | €11,054 | €4,904 |
| G&A Expenses | €2,660 | €2,611 | €2,635 | €2,338 |
| SG&A Expenses | €2,660 | €2,611 | €2,635 | €2,338 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €9,965 | €9,265 | €3,967 | €1,595 |
| Operating Expenses | €17,769 | €21,555 | €17,656 | €8,837 |
| Operating Income | -€16,489 | -€20,288 | -€17,115 | -€7,327 |
| % Margin | -919.6% | -1,127.1% | -1,186.1% | -180.4% |
| Other Income/Exp. Net | -€7,064 | -€39 | -€2,158 | -€255 |
| Pre-Tax Income | -€23,553 | -€20,327 | -€19,273 | -€7,582 |
| Tax Expense | €377 | €17 | €285 | €100 |
| Net Income | -€23,931 | -€20,344 | -€19,562 | -€5,937 |
| % Margin | -1,334.7% | -1,130.2% | -1,355.6% | -146.2% |
| EPS | -0.16 | -0.15 | -0.18 | -0.067 |
| % Growth | -6.7% | 16.7% | -167.5% | – |
| EPS Diluted | -0.16 | -0.15 | -0.18 | -0.067 |
| Weighted Avg Shares Out | 153,878 | 135,627 | 105,746 | 88,210 |
| Weighted Avg Shares Out Dil | 153,878 | 135,627 | 105,746 | 88,210 |
| Supplemental Information | – | – | – | – |
| Interest Income | €484 | €28 | €16 | €8 |
| Interest Expense | €313 | €66 | €2,197 | €1,214 |
| Depreciation & Amortization | €11,314 | €1,743 | €33 | €511 |
| EBITDA | -€12,062 | -€18,444 | -€17,037 | -€5,857 |
| % Margin | -672.7% | -1,024.7% | -1,180.7% | -144.2% |